CN102905534B - 治疗癌症的方法 - Google Patents

治疗癌症的方法 Download PDF

Info

Publication number
CN102905534B
CN102905534B CN201180019660.9A CN201180019660A CN102905534B CN 102905534 B CN102905534 B CN 102905534B CN 201180019660 A CN201180019660 A CN 201180019660A CN 102905534 B CN102905534 B CN 102905534B
Authority
CN
China
Prior art keywords
cells
tumor
cancer
exosomes
dendritic cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180019660.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN102905534A (zh
Inventor
约翰·W·霍拉迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icosos Heath Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN102905534A publication Critical patent/CN102905534A/zh
Application granted granted Critical
Publication of CN102905534B publication Critical patent/CN102905534B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
CN201180019660.9A 2010-04-06 2011-04-06 治疗癌症的方法 Expired - Fee Related CN102905534B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32137010P 2010-04-06 2010-04-06
US61/321,370 2010-04-06
PCT/US2011/031359 WO2011127129A1 (en) 2010-04-06 2011-04-06 Methods of treating cancer

Publications (2)

Publication Number Publication Date
CN102905534A CN102905534A (zh) 2013-01-30
CN102905534B true CN102905534B (zh) 2016-03-02

Family

ID=44763257

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180019660.9A Expired - Fee Related CN102905534B (zh) 2010-04-06 2011-04-06 治疗癌症的方法

Country Status (5)

Country Link
US (1) US9107878B2 (enExample)
EP (2) EP2555627A4 (enExample)
JP (2) JP6025707B2 (enExample)
CN (1) CN102905534B (enExample)
WO (1) WO2011127129A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6025707B2 (ja) 2010-04-06 2016-11-16 エクソサイト セラピューティクス ピーティイー リミテッド 癌を治療する方法
JP6272765B2 (ja) * 2012-10-01 2018-01-31 国立大学法人京都大学 ナノゲル／エキソソーム複合体とｄｄｓ
WO2017112919A1 (en) * 2015-12-23 2017-06-29 The Trustees Of Columbia University In The City Of New York Tissue-engineered three-dimensional model for tumor analysis
US10883083B2 (en) 2013-08-02 2021-01-05 The Trustees Of Columbia University In The City Of New York Tissue-engineered three-dimensional model for tumor analysis
CN104726410B (zh) * 2013-12-23 2019-09-17 浙江大学 一种具有免疫抑制功能的外排体及其应用
CN105505772B (zh) * 2015-12-07 2018-07-10 中国科学院苏州生物医学工程技术研究所 对单个外泌体进行裂解的装置
US20190125848A1 (en) * 2016-03-30 2019-05-02 Dana-Farber Cancer Institute, Inc. Dendritic cell-extracellular vesicle fusions and methods of using same
JP2018070572A (ja) * 2016-10-24 2018-05-10 義之 小山 免疫治療システム
JP6613499B2 (ja) * 2017-08-24 2019-12-04 学校法人藤田学園 細胞殺傷剤
US12241091B2 (en) * 2018-08-20 2025-03-04 Institute Of Process Engineering, Chinese Academy Of Sciences Method of making exosomes from tumor cell/antigen presenting cell hybrid cells
JP6635637B1 (ja) 2018-11-22 2020-01-29 株式会社細胞治療技術研究所 免疫療法ワクチンの製造方法
CN110036976B (zh) * 2019-05-08 2021-12-07 华南农业大学 一种阻断鸡禽白血病病毒垂直传播的方法及其应用
CN111759862A (zh) * 2020-06-04 2020-10-13 江苏大学 干细胞外泌体在制备抗结肠炎恶化药物中的应用
JP7160963B2 (ja) * 2021-01-15 2022-10-25 Ｖａｘｏｓｏｍｅ合同会社 細胞外粒子の製造方法
JP7079901B1 (ja) * 2021-08-24 2022-06-02 Ｖａｘｏｓｏｍｅ合同会社 細胞外粒子の産生方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605885A (en) * 1988-05-05 1997-02-25 Entremed, Inc. Method for stimulating the immune system
CN1446583A (zh) * 2002-11-29 2003-10-08 帕弗瑞生物技术(北京)有限公司 一种肿瘤免疫治疗及预防性疫苗的组成、制备、应用方案
US20040028692A1 (en) * 1997-07-16 2004-02-12 Laurence Zitvogel Sensitization process for antigen-presenting cells and means for implementing the process
CN101085349A (zh) * 2006-06-09 2007-12-12 项雯华 囊泡导向的免疫细胞及其在制备抗肿瘤药物上的应用
US20090123441A1 (en) * 2007-10-08 2009-05-14 Intrexon Corporation Engineered Dendritic Cells and Uses for the Treatment of Cancer

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0690671B1 (en) 1993-03-23 2004-08-04 Cbr Laboratories, Inc. Method and apparatus for encapsulation of biologically-active substances in cells
DE4410136A1 (de) * 1993-03-31 1994-10-06 Boehringer Mannheim Gmbh Tumorizide T-Lymphozyten
EP0698087A1 (en) * 1993-05-14 1996-02-28 Dr. L. Willems Instituut Human t cell monoclone, process for its production and its use, diagnostic of infectious diseases, autoimmune diseases, t-cell mediated allergies and cancer
US5610013A (en) * 1993-07-22 1997-03-11 Ludwig Institute For Cancer Research Method for diagnosing a disorder by determining expression of gage tumor rejection antigen precursors
US6773669B1 (en) 1995-03-10 2004-08-10 Maxcyte, Inc. Flow electroporation chamber and method
US6074605A (en) 1995-03-10 2000-06-13 Entremed, Inc. Flow electroporation chamber and method
US5720921A (en) 1995-03-10 1998-02-24 Entremed, Inc. Flow electroporation chamber and method
US6090617A (en) 1996-12-05 2000-07-18 Entremed, Inc. Flow electroporation chamber with electrodes having a crystalline metal nitride coating
US20020022036A1 (en) * 2000-08-21 2002-02-21 Riordan Neil H. Method for inducing an anti-tumor and anti-cachexia immune response in mammals
US7029916B2 (en) 2001-02-21 2006-04-18 Maxcyte, Inc. Apparatus and method for flow electroporation of biological samples
FR2827872A1 (fr) * 2001-07-30 2003-01-31 Roussy Inst Gustave Vesicules membranaires de fluide biologique preleve in vivo, leur preparation et utilisation dans la stimulation d'une reponse immunitaire
EP1456345B1 (en) 2001-08-22 2016-07-20 Maxcyte, Inc. Apparatus and method for electroporation of biological samples
AU2003277109A1 (en) 2002-09-30 2004-04-23 Maxcyte, Inc. Apparatus and method for streaming electroporation
WO2004053095A2 (en) * 2002-12-10 2004-06-24 Merix Bioscience, Inc. In situ maturation of dendritic cells
MXPA05008687A (es) * 2003-02-17 2005-10-05 Mebiopharm Co Ltd Remedio para cancer.
JP2006518219A (ja) * 2003-02-18 2006-08-10 マックスサイト インコーポレーティッド 電気穿孔法による細胞への抗原の負荷方法
US20060134067A1 (en) * 2003-02-18 2006-06-22 Maxcyte, Inc. Loading of cells with antigens by electroporation
US8247231B2 (en) * 2003-07-31 2012-08-21 Wilson Constance N Methods and compositions for producing antigenic responses
KR101131727B1 (ko) * 2004-06-11 2012-03-28 가톨릭대학교 산학협력단 ＣＥＡ-특이적인 세포독성 Ｔ세포를 생성하는 재조합 아데노바이러스 ＡｄＶＣＥＡ로 트랜스덕션된 수지상세포, 이를 포함하는 백신 및 약제학적 조성물
US8338173B2 (en) * 2005-08-11 2012-12-25 University College Cardiff Consultants Limited Preparation of antigen-presenting human γδ T cells and use in immunotherapy
JP4824389B2 (ja) * 2005-10-28 2011-11-30 株式会社医学生物学研究所 エプスタイン−バールウイルス感染細胞を特異的に攻撃する細胞傷害性ｔ細胞エピトープペプチド及びその用途
KR20090047290A (ko) * 2007-11-07 2009-05-12 주식회사 바이오인프라 엑소좀 및 이를 함유한 암 백신 조성물
KR101076879B1 (ko) 2008-04-11 2011-10-25 주식회사 하이닉스반도체 셀프 부스팅을 이용한 플래시 메모리소자의 프로그램 방법
EP2303319B1 (en) * 2008-06-20 2016-10-05 Duke University Compositions, methods and kits for eliciting an immune response
JP6025707B2 (ja) 2010-04-06 2016-11-16 エクソサイト セラピューティクス ピーティイー リミテッド 癌を治療する方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605885A (en) * 1988-05-05 1997-02-25 Entremed, Inc. Method for stimulating the immune system
US20040028692A1 (en) * 1997-07-16 2004-02-12 Laurence Zitvogel Sensitization process for antigen-presenting cells and means for implementing the process
CN1446583A (zh) * 2002-11-29 2003-10-08 帕弗瑞生物技术(北京)有限公司 一种肿瘤免疫治疗及预防性疫苗的组成、制备、应用方案
CN101085349A (zh) * 2006-06-09 2007-12-12 项雯华 囊泡导向的免疫细胞及其在制备抗肿瘤药物上的应用
US20090123441A1 (en) * 2007-10-08 2009-05-14 Intrexon Corporation Engineered Dendritic Cells and Uses for the Treatment of Cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CD83+ human dendritic cells transfected with tumor peptide cDNA by electroporation induce specific T-cell responses: A potential tool for gene immunotherapy;S Lohmann等;《Cancer gene therapy》;20001231;第7卷(第4期);605-614 *
Electroporation of viral transactivator proteins into lymphocyte suspension cells;F Kashanchi 等;《Nucleic acids research》;19921231;第20卷(第17期);4673-4674 *
外泌体及其抗肿瘤作用机制;郭芳 等;《生命的化学》;20071231;第27卷(第1期);72-75 *
树突状细胞在肿瘤中的研究进展;柯奇周;《国际肿瘤学杂志》;20060331;第33卷(第3期);179-181 *

Also Published As

Publication number Publication date
WO2011127129A1 (en) 2011-10-13
CN102905534A (zh) 2013-01-30
JP2013523824A (ja) 2013-06-17
US20130202644A1 (en) 2013-08-08
JP6025707B2 (ja) 2016-11-16
EP2555627A4 (en) 2013-10-23
JP2017002054A (ja) 2017-01-05
EP2555627A1 (en) 2013-02-13
EP3238782A2 (en) 2017-11-01
US9107878B2 (en) 2015-08-18
EP3238782A3 (en) 2018-01-03

Similar Documents

Publication Publication Date Title
CN102905534B (zh) 治疗癌症的方法
JP2022092001A (ja) 樹状細胞免疫療法
CN111840528A (zh) 外泌体联合免疫检查点阻断剂的肿瘤疫苗及其制备方法
EP2531207B1 (en) Methods and compositions for cancer immunotherapy using flagellin-tumor associated antigen fusion protein expressing tumor cells
WO2019001339A1 (zh) 一种新型的肿瘤疫苗及其用途
JP6773788B2 (ja) 小分子アブレーション化合物を用いたがん免疫治療のための生体外（Ｅｘ Ｖｉｖｏ：エクスビボ）での免疫細胞活性の増強方法
WO2014161887A1 (en) Targeted cancer immune therapy
JP2021533798A (ja) エクソソームに基づく抗腫瘍ワクチン
AU757443B2 (en) New apoptotic bodies, monocyte derived cells containing the same, a process for their preparation and their uses as vaccines
EP2938354A1 (en) Method for preparing an immunogenic lysate, the lysate obtained, dendritic cells loaded with such lysate and a pharmaceutical composition comprising the lysate or the dendritic cells
CN109106945B (zh) 用于治疗疾病的同种异体自噬体富集组合物
CN101636174B (zh) 抗肿瘤疫苗制备方法
CN103933558B (zh) 一种新型、广谱的治疗性肿瘤疫苗的制备和使用方法
Pan et al. Adenovirus mediated transfer of p53, GM-CSF and B7-1 suppresses growth and enhances immunogenicity of glioma cells
Dunn et al. Dendritic cells and HNSCC: a potential treatment option?
US20170095545A1 (en) Inhibition of tumor angiogenesis by checkpoint inhibitors and active vaccination
AU779325B2 (en) Melanoma vaccine and methods of making and using same
Shi et al. Anti-tumor effect and immune-related mechanism study of compound aluminum sulfate injection in transplanted tumor-bearing mice
Pang et al. Inhibitory effects of human AFP-derived peptide-pulsed dendritic cells on mouse hepatocellular carcinoma
Wilson et al. GSC Biological and Pharmaceutical Sciences
WO2016159286A1 (ja) 癌ワクチンの製造方法、及び癌ワクチン
WO2014087217A1 (en) Allogenic mesendritic vector for ovarian cancer
Yousefieh Gene therapy using Tet-repressor system to modulate prostate tumor microenvironment

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: QRXPHARMA PTY LTD.

Free format text: FORMER OWNER: HOLADAY JOHN W.

Effective date: 20140729

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20140729

Address after: Singapore City

Applicant after: Holaday John W

Address before: American Maryland

Applicant before: Holaday John W

C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20190925

Address after: Florida, USA

Patentee after: Icosos Heath Company

Address before: Singapore City

Patentee before: Exeter Medical Private Limited

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160302

Termination date: 20210406